Brief: Renovorx Enrolls First Patient In Ongoing Tiger-Pac Phase 3 Clinical Trial
22/02/2022 13:39
Feb 22 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX ENROLLS FIRST PANCREATIC CANCER PATIENT AT
COLUMBIA
UNIVERSITY’S NEW YORK-PRESBYTERIAN HOSPITAL IRVING MEDICAL
CENTER IN ONGOING TIGER-PAC PHASE 3 CLINICAL TRIAL
Source text for Eikon: ID:nBw7dhK4xa
Further company coverage: RNXT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer